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Introduction. Indirect immunofluorescence (IIF) is the gold standard method for the detection of antinuclear antibodies (ANA)
which are essential markers for the diagnosis of systemic autoimmune rheumatic diseases. For the discrimination of positive
and negative samples, we propose here an original approach named Immunofluorescence for Computed Antinuclear antibody
Rational Evaluation (ICARE) based on the calculation of a fluorescence index (FI).Methods. We made comparison between FI and
visual evaluations on 237 consecutive samples and on a cohort of 25 patients with SLE. Results. We obtained very good technical
performance of FI (95% sensitivity, 98% specificity, and a kappa of 0.92), even in a subgroup of weakly positive samples. A significant
correlation between quantification of FI and IIF ANA titers was found (Spearman’s 𝜌 = 0.80, 𝑃 < 0.0001). Clinical performance
of ICARE was validated on a cohort of patients with SLE corroborating the fact that FI could represent an attractive alternative for
the evaluation of antibody titer. Conclusion. Our results represent a major step for automated quantification of IIF ANA, opening
attractive perspectives such as rapid sample screening and laboratory standardization.
1. Introduction
Antinuclear antibodies (ANA) are essential biological mark-
ers for the diagnosis [1], classification, and disease activity
monitoring [2] of systemic autoimmune rheumatic diseases.
Given this central role, ANA screening should be accurate
and reproducible. For several decades, indirect immunoflu-
orescence (IIF) on HEp-2 cells has been the reference tech-
nique for ANA testing. Although new available techniques
[3, 4] such as ELISA or multiplexing solid phase technologies
have been proposed to replace IIF, the American College
of Rheumatology (ACR) still recommends IIF as the gold
standard method for ANA detection [5]. The main drawback
of this technique is IIF reading subjectivity, intra- and
interlaboratory variabilities complicating the standardization
expected in modern laboratories.
Recently, commercial automated systems for ANA IIF
reading and interpretation have become available and were
described in the literature [6–11]. Most of them are based
on data mining and supervised machine learning methods
[12]. In addition to their complexity, they share a common
weakness in the detection of weak positivity.
In this work, we describe an original algorithm named
Immunofluorescence for Computed Antinuclear antibody
Rational Evaluation (ICARE) for automation of IIF ANA
evaluation offering excellent analytical performance and an
attractive quantitative approach for positive/negative dis-
crimination. We assess the quantification of the fluorescence
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Table 1: Characteristics of patients from the routine and SLE cohorts.
ANA 𝑛 Men Women Mean age (years) Age std. (years) Range (years)
Routine cohort
(𝑛 = 237)
Negative 103 50 53 45.7 21.4 3–90
Positive 134 43 91 52.3 18.7 8–89
Titer = 100 49 24 25 56.4 18.7 11–50
Titer ≥ 200 85 19 66 49.9 18.5 8–89
SLE cohort
(𝑛 = 25)
Negative 1 0 1 n/a n/a n/a
Positive 24 7 17 36.9 15.6 17–74
n/a: nonapplicable.
intensity as an alternative to antibody titer evaluation and
validate our approach in a population of patients with
systemic lupus erythematosus (SLE).
2. Materials and Methods
2.1. Patients and Serum Samples. We collected serum sam-
ples from 2 cohorts of patients: a “routine cohort” and a
“SLE cohort”. The routine cohort comprised 237 consecutive
serum samples sent to the Immunology Laboratory for ANA
analysis with IIF for outpatients or patients hospitalized
in the Departments of Internal Medicine, Rheumatology,
Dermatology and Cardiology of the University Hospitals of
Assistance Publique-Hoˆpitaux de Marseille (AP-HM). The
SLE cohort comprised 25 consecutive SLE patients meeting
the American College of Rheumatology (ACR) classification
criteria and followed up in the Nephrology Department of
AP-HM. For all the SLE cohort patients, anti-double stranded
DNA (ds-DNA) antibody levels were measured in sera with
fluorescence-enzyme immunoassay (EliA dsDNA; Phadia,
Uppsala, Sweden; now part of Thermo Fisher Scientific). All
sera were retrospectively obtained from a declared serum
bank (BiobankDC2012-1704).This study did not need ethical
approval or consent.
2.2. Patients Characteristics. The routine cohort comprised
237 patients, 93 males and 144 females, with a mean age of
49.4 years (range 3–90 years) (Table 1). Based on visual IIF
ANA analysis, this cohort was splitted into ANA negative
(𝑛 = 103) and ANA positive (𝑛 = 134) sera. As expected,
there were significantly more women in the ANA IIF positive
group than in the ANA IIF negative group (70% versus 51%,
𝑃 = 0.01).
In the positive ANA IIF group, several single and
mixed fluorescence patterns were represented (91 speckled,
10 centromeric, 7 nucleolar, 5 homogenous, 5 nuclear dots,
3 mitotic spindle apparatus, 11 homogenous-speckled, and
2 homogenous-nucleolar). The fluorescence titers ranged
from 100 to more than 800. To analyze more accurately the
sensitivity for weak positive detection, the ANA IIF positive
groupwas subdivided intoweak positiveANA IIF (titer = 100,
𝑛 = 49, 24 males and 25 females, mean age 56.4 years, range:
11–50) and positive ANA IIF (ANA titer ≥ 200, 𝑛 = 85, 19
males and 66 females, mean age 49.9 years, range: 8–89)
The SLE cohort comprised 25 patients, 7 males and 18
females, with a mean age of 37.2 years (range 17–74 years)
(Table 1). Except for one patient, all patients were ANA
positive (11 homogenous-speckled, 13 speckled) with ANA
IIF titers ranging from 200 to above 800. Eight patients
were negative for anti-dsDNA antibodies (antibody level <
16 IU/mL) and seventeen patients were positive (range: from
16 IU/mL to above 379 IU/mL).
2.3. ANA Testing. ANA in patients’ sera were detected by
commercial ANAHEp-2 indirect immunofluorescence assay.
Automated instrument (PhD system, Bio-Rad Laboratories,
Hercules, CA) was used for IIF slide preparation. Samples
diluted in phosphate buffered saline were incubated on HEp-
2 cells fixed on glass slides (Kallestad HEp-2 Cell Line Sub-
strate, 12wells slides, Bio-Rad Laboratories, Hercules, CA) for
30minutes at room temperature (RT).The screening dilution
was 1 : 100. After washing, bound antibodies were detected
by incubation with fluorescein isothiocyanate (FITC) con-
jugated sheep anti-human immunoglobulin (Kallestad FITC
conjugate, Bio-Rad Laboratories, Hercules, CA) for 30 min-
utes at RT. Subsequently, slides were washed, embedded with
a 4,6-diamidino-2-phenylindole (DAPI) containing medium
(Vectashield, Vector Laboratories Inc., Burlingame, CA),
and visually assessed with a fluorescence microscope (Leica
DM1000, LeicaMicrosystems, Germany) by two experienced
observers. For each sample, fluorescence pattern and titer
were visually assigned in case of positivity. The visual cut-
off titer was 100 corresponding to sera with weak positivity.
Based on visual ANA analysis, three patient groups were
created: positive ANA (titer ≥ 200), weakly positive ANA
(titer = 100), and negative ANA groups.The titer was defined
as the reciprocal of the highest dilution of serum that still
shows immunofluorescent nuclear staining.
2.4. Image Capture. For each patient, two images of the same
central microscopic field were captured with 20x objective at
two different excitation wavelengths: 480 nm for FITC stain
and 360 nm for DAPI stain. Captures were performed with
a fluorescence microscope (Leica DM1000, Leica Microsys-
tems, Germany) equipped with 360 nm and 480 nm leds for
excitation (FluoLed, Fraen corporation Srl, SettimoMilanese,
Italy). Captures with 1392 × 1040 pixels resolution were
performed with a color CCD camera (Infinity 2, Lumenera
Corporation, Ottawa, Canada). Exposure times for FITC and
DAPI captures were 200ms and 300ms, respectively. All
captured color images were 24 bit-depth and have been saved
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Figure 1: Examples of captured images. Examples of images
obtained by IIF on HEp-2 cells from 2 different serum samples: one
ANA negative ((a), (b)) and one ANA positive ((c), (d)) for both
DAPI ((a), (c)) and FITC ((b), (d)) stainings. Objective: ×20.
in Tagged Image File Format (TIFF) for subsequent analysis.
As an example, Figure 1 shows the IIF microscopic images
obtained from one positive and one negative sera.
2.5. ICARE Algorithm Description for Image Analysis. First,
using image analysis software, we splitted RGB color channels
and kept blue or green channel for DAPI and FITC images,
respectively. Then, DAPI image was used to determine
nucleus position. This was performed using a thresholding
method based on image histogram analysis. We defined the
background intensity of DAPI image as the first peak of DAPI
histogram. A threshold defined as twice this background
intensity allowed appropriate segmentation and selection of
nucleus region of DAPI image. This nucleus region selection
was then superimposed on FITC image which allowed mean
fluorescence intensity measurement of nucleus region of
FITC image (MFI n). Then, an inversion of selection allowed
mean fluorescence intensity measurement of non-nucleus
background region of FITC image (MFI b).
2.6. ICARE Index Calculation. For each captured well, we
defined a nondimensional index called fluorescence index
(FI) and calculated as follows: FI = (MFI n)/(MFI b).
The reproducibility of FI was tested. A single sample with
weakly positive ANA (titer = 100) was tested 10 times in 10
wells each day on 3 consecutive days. Coefficients of variation
of FI on the 3 days were 8.6%, 8.7%, and 5.9%.
We also evaluated the effect of exposure time of the
camera on FI by studying the FI as a function of the time-
exposure (50–300ms) for positive ANA patients (data not
shown). No variation was observed attesting that FI values
were time-exposure independent.
2.7. Statistics. Analytical performance of ICARE algorithm
was evaluated by calculating sensitivity (Se.), specificity
Table 2: Analytical performance of ICARE algorithm for ANA
screening.
Positive versus negative Weakly positiveversus negative
Sensitivity 94.5% 85.7%
Specificity 98.1% 98.1%
PPV 98.5% 95.5%
NPV 93.5% 93.5%
Kappa 0.923 0.861
PPV: positive predictive value, NPV: negative predictive value.
Kappa: Cohen’s kappa coefficient.
(Spe.), positive predictive value (PPV), and negative predic-
tive value (NPV). Accuracy was defined as the proportion of
the total number of correct predictions by FI. Mann-Whitney
𝑈 test was used to compare the mean values of FI and Spear-
man’s rank correlation coefficient to study the correlation
between FI and IIFANA titers.The agreement between visual
and algorithmic interpretation was evaluated using Cohen’s
Kappa coefficient which takes on the value (i) zero if there
was no more agreement between two tests than expected by
chance (ii) 1 if there was a perfect agreement. Kappa values
below 0.4were considered as poor agreement, values between
0.4 and 0.75 as fair to good agreement, and values higher
than 0.75 as excellent agreement as described [13]. Data were
analyzed and curves plotted using R statistical software (R
Foundation for Statistical Computing, Vienna, Austria) and
Microsoft Excel 2007.The threshold for statistical significance
was set at 𝑃 = 0.05.
3. Results
3.1. Index Cut-Off Determination and Analytical Performance
of ICARE Algorithm Performed on Routine Cohort. FI was
calculated for the 237 patients from the routine cohort. As
shown in Figure 2(a), FI was significantly higher in ANA
positive patients compared to ANA negative patients (mean
value: 2.06 ± 1.18 versus 1.13 ± 0.06, 𝑃 < 0.0001). To test
further the ICARE algorithm performance in weakly positive
samples (ANA titer of 100 corresponding to the visual cut-
off), we compared samples with very low positive ANA to
sampleswith negativeANA. Interestingly, FI was significantly
higher in patients with weakly positive ANA than in patients
with negative ANA (mean value: 1.33 ± 0.11 versus 1.13 ± 0.06,
𝑃 < 0.0001) (Figure 2(b)).
Cut-off determination of FI was performed using ROC
analysis (Figure 3(a)) and accuracy curve (Figure 3(b)). FI
cut-off value was set at 1.246 and area under the curve
(AUC) was 0.991, attesting the excellent performance of the
algorithm.
For the whole ANA IIF positive group (including
weakly positive samples), sensitivity and specificity for posi-
tive/negative discriminationwere, respectively, 95% and 98%.
The concordance between visual and algorithmic evaluation
was also excellent, with a Cohen’s kappa of 0.923 (Table 2).
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Figure 2: Fluorescence index in samples from the routine cohort (𝑛 = 237). (a) Comparison of samples with negative versus positive ANA in
IIF. (b) Comparison of samples with negative versus weakly positive (titer = 100) ANA in IIF. Indexes were calculated with ICARE algorithm
from captured IIF images and plotted for positive ANA patients (titer ≥ 100, 𝑛 = 134), weakly positive ANA patients (titer = 100, 𝑛 = 49), and
negative ANA patients (titer < 100, 𝑛 = 103). The box plots show the median value and range from the first to the third quartile. The whiskers
extend between the maximum and the minimum indices. Indexes from ANA positive patients as well as those from weakly positive patients
were significantly higher than those from ANA negative patients (𝑃 < 0.0001, Mann-Whitney 𝑈 test).
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Figure 3: Cut-off determination for fluorescence index. (a) Receiver operating characteristic (ROC) of ANA screening with algorithm
evaluation. Sens.: sensitivity, Spec.: specificity, PV+: positive predictive value, and PV−: negative predictive value. (b) Accuracy as a function
of fluorescence index cut-off. Accuracy is the ratio between the number of correct prediction with algorithm and the total number of patients.
Here the calculated cut-off is 1.246.
For weakly positive samples only, ICARE algorithm
performancewas also very goodwith 86% sensitivity and 98%
specificity and a coefficient of concordance (Kappa) of 0.86.
3.2. Result Comparison between ICARE Algorithm and Visual
ANA IIF. Concordant results between ICARE algorithm and
visual evaluation of ANA by IIF were obtained for 228/237
routine samples (96%) (Table 3). The 9 remaining samples
showed discrepant results: 2 were classified as weakly positive
by the ICARE algorithm and negative by visual examination
(false positive) and 7 were classified as negative by the ICARE
algorithm but visually recognized as weakly positive by the
expert (false negative). None of the false negative samples
were associated with positive extractable nuclear antigen
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Table 3: ANA screening agreement between visual and ICARE eval-
uations.
ICARE+ ICARE− Total
Visual+ 127 7 134
Visual− 2 101 103
Total 129 108 237
(ENA) or anti-dsDNA antibodies, and among them, 3 were
drawn in an infectious context, 1 was from a 75-year-old
patient and 1 from a patient treated for psoriatic arthritis with
previously negative ANA. Importantly, no false negative was
observed for samples with an ANA IIF titer ≥ 200.
3.3. Quantification of Fluorescence Index as an Alternative to
ANA Titer. To assess the usefulness of FI quantitatively, as an
alternative to antibody titer, we first investigated the effect of
sample dilution on FI values. Twenty ANA positive samples
with 5 different staining patterns (speckled, homogenous,
centromeric, nucleolar, and nuclear dots) were diluted from
1 : 100 to 1 : 800. FI was evaluated for each dilution of a given
sample (Figure 4). For all samples tested, a decrease in FI was
obtained when the dilution factor increased, whatever the
staining pattern tested. To comfort the relationship between
FI values and antibody levels, we then analyzed FI value
as a function of titer in 87 ANA positive speckled samples
(Figure 5). A significant correlation between FI and ANA
titers was found (Spearman’s 𝜌 = 0.78; 𝑃 < 0.0001).
3.4. Clinical Validation on Patients with SLE. In order to
evaluate the clinical performance of ICARE algorithm in
connective tissue diseases, patients from the SLE cohort were
tested. In agreement with our previous results, a significant
correlation was found between FI and ANA titer (Spearman’s
𝜌 = 0.8; 𝑃 < 0.0001) (Table 4). Interestingly, a significant
correlation was also observed between FI and anti-dsDNA
antibody levels in this cohort (Spearman’s𝜌 = 0.47;𝑃 < 0.01).
4. Discussion
In this study we propose an original approach for automation
of ANA IIF based on the calculation of a fluorescence index to
discriminate positive and negative samples in a reproducible
and nonobserver-biased way. We demonstrate excellent ana-
lytical performance of ICARE algorithm in comparison to
the gold standard IIF visual method. Moreover, we show that
FI could be used as a quantitative value to evaluate ANA
titers. Last, we show that ICARE has potential interest in the
monitoring of ANA in SLE patients.
Our approach is based on a quantitative strategy that
mimics the routine analysis of ANA IIF. In the routine
practice, the first step of this analysis consists in posi-
tive/negative screening that allows the rapid reporting of the
60–70% negative results requiring no further investigation.
The second step is the pattern recognition, which is under
development.
In the study, for the screening of 237 samples, ICARE
reached a sensitivity of 95%a specificity of 98%and evidenced
Table 4: Correlations of FI with anti-dsDNA antibody levels and IFI
titer.
Parameter IFI titer Anti-dsDNA
Spearman’s 𝜌 0.80 0.47
𝑃 value (two-tailed) <0.0001 0.02
an excellent concordance with the visual method (accuracy:
96.2%, kappa = 0.923). To analyze more accurately the
ICARE performance, analysis was performed on an ANA IIF
subgroup presenting a weak positivity defining the visual cut-
off (titer = 100). In this more difficult design, performance
of ICARE was also very good with 86% of sensitivity, 98% of
specificity, and an excellent coefficient of concordance (kappa
= 0.86). The very good performance of ICARE suggests that
it could replace the screening routine step by an automated
approach.
Several commercially available systems are available for
automated analysis of ANA by IIF: Aklides (Medipan,
Berlin, Germany), G-Sight (Menarini, Florence, Italy), and
EuroPattern (Euroimmun, Lu¨beck). In routine activity, good
performance for ANA screening are reported. However,
performance was not specifically evaluated in low positive
ANA samples. This could change the interpretation of the
results for the benefit of elevated positivity (high endpoint
titers). Additionally, for Aklides system, Egerer et al. found
a screening sensitivity of 94% for the whole population
studied [6], while on the same system, Melegari et al. [7]
found sensitivity of only 72% and suggested reassessing the
cut-off for the detection of weakly positive samples. In the
literature, the percentage of concordance between visual IIF
and automated measures varied from 86% to 99%.With 96%
of concordant results, our method is thus among the most
performing. In our study, the only discrepant results (3.8%)
were at the visual cut-off titer. The majority (7/9) were found
weakly positive by the visual method. It is well known in
laboratory practice that IIF visual reading becomes highly
subjective and variable between observers when fluorescence
intensity is around the cut-off titer. Moreover, none of the
7 samples were associated with positive extractable nuclear
antigen (ENA) or anti-dsDNA antibodies, and other clinical
settings than autoimmune disease may explain these visual
low levels of ANA in some of them. Low titers of ANA
may indeed be present in healthy aged subjects and patients
with infections or with cancer [14]. This suggests higher
performance of ICARE compared to visual methods and
promotes an automated evaluation of ANA screening.
Only one system in the literature presents an “index,”
but it is statistical, not quantitative, and is defined as a
probability index. Indeed, for screening purpose, G-sight
system provides a probability of positivity based on statistics
of a set of previous training samples [10].The fact that ICARE
method, for automated evaluation of IIF ANA, was based
on a quantitative evaluation opens attractive perspectives.
We showed a significant correlation between the fluores-
cence index and ANA titers of the samples, suggesting that
FI reflects the antibody level. Titer prediction with auto-
mated system could improve cost efficiency by suppressing
6 Clinical and Developmental Immunology
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Figure 4: Study of fluorescence index as a function of dilution. Twenty ANA positive samples with different fluorescence patterns were
diluted from 1 : 100 to 1 : 800. For each fluorescence pattern, four representative sampleswere diluted. For each sample, one curve represents the
fluorescence index plotted as a function of dilution factor. SP: speckled, NU: nucleolar, H: homogenous, ND: nuclear dots, HSP: homogenous-
speckled, and CE: centromeric.
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Figure 5: Correlation between fluorescence index and ANA titer.
Calculated indices from patients with ANA positive speckled pat-
tern (𝑛 = 87) were plotted as a function of the endpoint titer. The
box plots show the median value and range from the first to the
third quartile. The whiskers extend between the maximum and the
minimum indices. There is a correlation between the fluorescence
index and the fluorescence endpoint titer (Spearman’s 𝜌 = 0.78,
𝑃 < 0.0001).
the need of serial dilution and speeding up the report of
the results. This quantitative index could give a compar-
ative scale between laboratories allowing, in the future, a
possible standardization of methods. Moreover, we validated
this quantitative approach in a population of SLE patients.
Interestingly, we also found a significant correlation between
FI and anti-dsDNA antibody levels, which suggests a possible
interest of FI in SLE disease activity monitoring.
In conclusion, the automated discrimination between
positive and negative results represents a major step for auto-
mated evaluation of antinuclear autoantibodies by indirect
immunofluorescence. Although ICARE algorithm should be
tested in a multicenter analysis, it already presents several
benefits such as the detection of weakly positive samples and
a quantitative fluorescence index determination.
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